Table 1 Characteristics of 229 HIV-infected patients co-infected with tuberculosis
From: The impact of HAART initiation timing on HIV-TB co-infected patients, a retrospective cohort study
|  | Died (n = 60, 26.2%) | Survived (n = 169) | Total (n = 229) |
|---|---|---|---|
TB diagnosis year | Â | Â | Â |
  1997–2000 | 12 (20.3%) | 47 (79.7%) | 59 {25.8%} |
  2001–2003 | 19 (29.2%) | 46 (70.8%) | 65 {28.4%} |
  2004–2006 | 29 (27.6%) | 76 (72.4%) | 105 {45.9%} |
Age (yrs) at first TB diagnosis, median [IQR]$ | 42.1 [33.3-53.5] | 36.8 [32.4-43.6] | 37.5 [32.5-47.1] |
  Male | 55 (25.6%) | 160 (74.4%) | 215 {93.9%} |
  Female | 5 (35.7%) | 9 (64.3%) | 14 {6.1%} |
HIV transmission category | Â | Â | Â |
  MSM | 18 (20.0%) | 72 (80.0%) | 90 {39.3%} |
  Heterosexual contacts | 33 (39.7%) | 78 (70.3%) | 111 {48.5%} |
  IDUs | 4 (19.1%) | 17 (81.0%) | 21 {9.2%} |
  Other/undefined | 5 (71.4%) | 2 (28.6%) | 7 {3.1%} |
CD4 count (/mm3) at TB diagnosis, median [IQR] | 22 [7-85] | 43 [20-117] | 40 [17-107] |
  ≤50 | 32 (25.2%) | 95 (74.8%) | 127 {55.5%} |
  51–100 | 9 (25.0%) | 27 (75.0%) | 36 {15.7%} |
  101–200 | 8 (33.3%) | 16 (66.7%) | 24 {10.5%} |
  ≥200 | 3 (9.7%) | 28 (90.3%) | 31 {13.5%} |
  No data | 8 (72.7%) | 3 (27.3%) | 11 {4.8%} |
Localization of tuberculosis | Â | Â | Â |
  Pulmonary | 22 (26.8%) | 60 (73.2%) | 82 {35.8%} |
  PTB+ extra-pulmonary | 37 (28.2%) | 94 (71.8%) | 131 {57.2%} |
  Extra-pulmonary | 1 (6.3%) | 15 (93.8%) | 20 {7.0%} |
Laboratory findings | Â | Â | Â |
  Positive AFS smear | 46 [76.7%] | 127 [75.2%] | 173 {75.6%} |
  Positive MTB culture | 49 [81.7%] | 139 [82.3%] | 188 {82.1%} |
HAART during anti-TB treatment$ | Â | Â | Â |
  No | 30 (66.7%) | 15 (33.3%) | 45 {19.7%} |
  Yes | 30 (16.3%) | 154 (83.7%) | 184 {80.3%} |
IRIS* | 5 (8.8%) | 52 (91.2%) | 57 {31.0%}* |
HBV (+)# | 7 [11.7%] | 29 [17.2%] | 36 {15.7%} |
HCV (+)# | 5 [8.3%] | 22 [13.0%] | 27 {11.8%} |